EUVIMEDEUVIMED entdecken
Multizentrische StudieKlinische Studie (Phase I)Klinische Studie (Phase II)

CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease

Rabi Hanna iD, Haydar Frangoul iD, Luis Pineiro, Christopher McKinney, Markus Mapara, Jignesh Dalal, Hemalatha G Rangarajan, Harold Atkins, Akshay Sharma iD, Kai-Hsin Chang, Michael C Jaskolka, Keunpyo Kim iD und 5 weitere

New England Journal of Medicine · 02.04.2026 · 394 (13) · 1281-1291

DOI: 10.1056/nejmoa2415550 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift New England Journal of Medicine, erschienen am 02.04.2026. Verfasst von Rabi Hanna und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, CRISPR-Cas Systems, Fetal Hemoglobin, gamma-Globins. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Editas Medicine, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellCRISPR-Cas SystemsFetal Hemoglobingamma-GlobinsGenetic TherapyHematopoietic Stem Cell TransplantationVaso-Occlusive CrisesAdolescentAdultFemaleHumansMaleYoung AdultGene EditingPromoter Regions, GeneticSeverity of Illness IndexFollow-Up StudiesTransplantation, AutologousTransplantation ConditioningRepressor ProteinsBusulfanMyeloablative AgonistsTreatment Outcome

Substanzen

BCL11A protein, humanFetal Hemoglobingamma-GlobinsRepressor ProteinsBusulfanMyeloablative Agonists

Autor:innen und Institutionen

  • Department of Pediatric Hematology, Oncology, and Blood and Marrow Transplantation, Cleveland Clinic, Cleveland.
  • Sarah Cannon Research Institute, Nashville.
  • TriStar Centennial Children's Hospital, Nashville.
  • Blood and Marrow Transplant Program and Marrow Processing Laboratory, Baylor University Medical Center, Dallas.
  • Department of Pediatrics, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora.
  • Bone Marrow Transplantation and Cell Therapy Program, Columbia University Irving Medical Center, New York.

ORCID-Profile: Rabi Hanna, Haydar Frangoul, Akshay Sharma, Keunpyo Kim, Mark C Walters

Förderung

  • Editas Medicine, Inc.

Zitieren

APA

Hanna, R., Frangoul, H., Pineiro, L., McKinney, C., Mapara, M., Dalal, J., Rangarajan, H. G., Atkins, H., Sharma, A., Chang, K. H., Jaskolka, M. C., Kim, K., Yu, Q., Mei, B., Afonja, O., Walters, M. C., & RUBY Investigators (2026). CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. New England Journal of Medicine, 394(13), 1281-1291. https://doi.org/10.1056/nejmoa2415550

Vancouver

Hanna R, Frangoul H, Pineiro L, McKinney C, Mapara M, Dalal J, et al. CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease. New England Journal of Medicine. 2026;394(13):1281-1291. doi:10.1056/nejmoa2415550

BibTeX
@article{Hanna2026,
  author = {Hanna, Rabi and Frangoul, Haydar and Pineiro, Luis and McKinney, Christopher and Mapara, Markus and Dalal, Jignesh and Rangarajan, Hemalatha G and Atkins, Harold and Sharma, Akshay and Chang, Kai-Hsin and Jaskolka, Michael C and Kim, Keunpyo and Yu, Qifeng and Mei, Baisong and Afonja, Olubunmi and Walters, Mark C and RUBY Investigators, RUBY Investigators},
  title = {CRISPR-Cas12a Gene Editing of HBG1 and HBG2 Promoters to Treat Sickle Cell Disease},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {13},
  pages = {1281--1291},
  doi = {10.1056/nejmoa2415550}
}
Kostenlos starten →